Questions Raised About Invokana Label Expansion For Cv Risk Reduction | Latest News RSS feed

Questions Raised About Invokana Label Expansion For Cv Risk Reduction - Latest News


Amarin's Mineral Menace

The FDA briefing documents raised questions about the mineral ... the FDA said Amarin had to show a reduction in major cardiovascular events in the REDUCE-IT study prior to gaining the label expansion ... read more

EMDAC Wants Cardiovascular Outcomes for Vascepa

When it came to the main point of discussion, and the potential efficacy of Vascepa at reducing cardiovascular risk, there were many questions raised. Committee member ... vote in the 10/16 Panel on V... read more

Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript

We also filed ACZ885 for CV risk reduction in both US and Europe ... And in anticipation again of the expansion of the label soon. So, I think so far so good. Yes, we expect that we'll see the traject... read more

Looking for another news?


Major new research study to demonstrate value of PET scans in Alzheimer's disease diagnosis

"I am confident that, at the end of this study, we will have amassed sufficient data to assess whether amyloid imaging has a positive impact on patient outcomes leading to expansion of beneficiary ... ... read more


Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials

Tissues stiffen during aging and during the pathological progression of cancer, fibrosis, and cardiovascular disease. Extracellular matrix stiffness is emerging as a prominent mechanical cue that prec... read more

Update on California bill AB 2109: It moves on despite the antivaccine movement

Science 2.0 is where scientists are the journalists. We are a science education nonprofit operating under Section 501(c)(3) of the Internal Revenue Code. Please make a tax-deductible donation if you v... read more

Pharma news highlights: Eli Lilly, Abbott and more

It would not be a stretch to say that this figure has doubled to 40 percent, yet solanezumab still remains a Phase III asset where the risk is likely higher than normal.” Abbott’s CV mistake Another . ... read more

Einstein, insanity and the war on drugs

a deadline that also applied to “significant and measurable results in the field of demand reduction.” The clock is ticking towards midnight, December 31, 2008. read more

5 Ways to Help Farm Animals

Less than 1 percent of farm animals are raised on pasture ... it is better for people too—reducing the risk of a number of chronic, preventable diseases, including cancer, cardiovascular disease, diab... read more

Unravelling the impact of ethnicity on health in Europe: the HELIUS study

For example, the identification of the main risk factors for cardiovascular disease ... discrimination and perceived general health, mental health problems, and raised blood pressure [41, 42]. Many qu... read more

Abiomed Inc (ABMD) Q2 2019 Earnings Conference Call Transcript

We'll then open the call to your questions. Before we begin ... we recognize that with the expansion of the labels both for high-risk PCI and cardiomyopathy and other forms of shock, we wanted to main... read more

Novartis AG (NVS) Q1 2018 Results - Earnings Call Transcript

We also filed ACZ885 for CV risk reduction ... smart margin expansion to enable us to get into the profitability range of our peers. And we'll keep you posted on our decision-making process. Thank you ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us